{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:49:18Z","timestamp":1792705758326,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["777357"],"award-info":[{"award-number":["777357"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020542","name":"Arthritis Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.coph.2022.102242","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T04:47:53Z","timestamp":1653194873000},"page":"102242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Immune tolerance therapies for autoimmune diseases: Shifting the goalpost to cure"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-1290","authenticated-orcid":false,"given":"Patrick","family":"Sharkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-8386","authenticated-orcid":false,"given":"Ranjeny","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102242_bib1","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2665-9913(20)30344-1","article-title":"Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy","author":"Nel","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib2","doi-asserted-by":"crossref","first-page":"e1315","DOI":"10.1002\/cti2.1315","article-title":"Proinsulin-specific T-cell responses correlate with estimated c-peptide and predict partial remission duration in type 1 diabetes","volume":"10","author":"Musthaffa","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.coph.2022.102242_bib3","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.coph.2022.102242_sref4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102242_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","article-title":"Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction","volume":"14","author":"Holers","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib6","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coph.2022.102242_bib7","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1172\/JCI45790","article-title":"The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans","volume":"121","author":"Menard","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2022.102242_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.40430","article-title":"Increased circulating follicular Treg cells are associated with lower levels of autoantibodies in patients with rheumatoid arthritis in stable remission","volume":"70","author":"Liu","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_sref9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/art.40424","article-title":"The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary sj\u00f6gren's syndrome","volume":"70","author":"Fonseca","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib11","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"56","author":"van Dongen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102242_bib12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/art.40062","article-title":"Brief report: clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: a trial of methotrexate versus placebo in undifferentiated arthritis as an example","volume":"69","author":"Burgers","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2012-202967","article-title":"Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study)","volume":"73","author":"van Aken","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-018-1702-0","article-title":"Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor","volume":"20","author":"Hjorton","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102242_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.coph.2022.102242_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41584-021-00639-6","article-title":"Insights into the biology and therapeutic implications of TNF and regulatory T cells","volume":"17","author":"Salomon","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2007.084269","article-title":"Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?","volume":"67","author":"Saleem","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/annrheumdis-2013-204882","article-title":"A\u00a0randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102242_sref20","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/art.40920","article-title":"N-linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis","volume":"71","author":"Hafkenscheid","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_sref21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5327","article-title":"Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis","volume":"12","author":"Kristyanto","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102242_bib22","doi-asserted-by":"crossref","first-page":"eabm1759","DOI":"10.1126\/sciadv.abm1759","article-title":"Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation","volume":"8","author":"Kissel","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.coph.2022.102242_sref23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/cei\/uxab008","article-title":"Evaluation of a fit-for-purpose assay to monitor antigen-specific functional CD4+ T cell subpopulations in rheumatoid arthritis using flow-cytometry based peptide-MHC class-II tetramer staining","volume":"207","author":"Patel","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2022.102242_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.40768","article-title":"Citrullinated aggrecan epitopes as targets of auto-reactive CD4+ T cells in patients with rheumatoid arthritis","volume":"71","author":"Rims","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2018.04.004","article-title":"Memory T cells specific to citrullinated alpha-enolase are enriched in the rheumatic joint","volume":"92","author":"Pieper","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.coph.2022.102242_bib27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2022.102242_bib28","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.3389\/fimmu.2019.02709","article-title":"T-follicular regulatory cells: potential therapeutic targets in rheumatoid arthritis","volume":"10","author":"Ding","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2022.102242_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102242_bib30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-021-02612-w","article-title":"Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis","volume":"23","author":"Hirose","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102242_sref32","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.4049\/jimmunol.1001311","article-title":"Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells","volume":"185","author":"Platt","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coph.2022.102242_bib33","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.2337\/db14-0047","article-title":"Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline","volume":"63","author":"Orban","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2022.102242_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126136","article-title":"B\u00a0lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes","volume":"4","author":"Linsley","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2022.102242_bib35","first-page":"73","article-title":"Abatacept reverses subclinical arthritis in patients with high-risk to develop rheumatoid arthritis -results from the randomized, placebo-controlled ARIAA Study in RA-at Risk Patients [abstract]","author":"Rech","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1084\/jem.20182287","article-title":"Taming autoimmunity: translating antigen-specific approaches to induce immune tolerance","volume":"216","author":"Carballido","year":"2019","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.coph.2022.102242_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/23808993.2021.1857237","article-title":"Clinical application of personalized rheumatoid arthritis risk information: translational epidemiology leading to precision medicine","volume":"6","author":"Sparks","year":"2021","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"10.1016\/j.coph.2022.102242_bib38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrrheum.2016.131","article-title":"Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?","volume":"12","author":"van der Vlist","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_sref39","doi-asserted-by":"crossref","first-page":"290ra287","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102242_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102242_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102242_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126025","article-title":"PD-L1- and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease","volume":"4","author":"Galea","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2022.102242_bib44","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4049\/jimmunol.1901128","article-title":"Regulatory T cells induced by single-peptide liposome immunotherapy suppress islet-specific T cell responses to multiple antigens and protect from autoimmune diabetes","volume":"204","author":"Bergot","year":"2020","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coph.2022.102242_bib45","first-page":"4920","volume":"71","author":"Sonigra","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_sref46","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102242_bib47","first-page":"1907","article-title":"Modified anti-CD3 therapy in psoriatic arthritis: a phase I\/II clinical trial","volume":"29","author":"Utset","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_bib48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102242_bib50","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102242_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coph.2022.102242_bib52","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102242_bib53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102242_sref54","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102242_bib55","doi-asserted-by":"crossref","first-page":"742719","DOI":"10.3389\/fimmu.2021.742719","article-title":"Driving CARs to BARs: the winding road to specific regulatory T cells for tolerance","volume":"12","author":"Scott","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2022.102242_sref56","doi-asserted-by":"crossref","first-page":"e066452","DOI":"10.1136\/bmj-2021-066452","article-title":"Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial","volume":"376","author":"Hahn","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.coph.2022.102242_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/imj.15537","article-title":"Rheumatoid arthritis is a preventable disease: 11 ways to reduce your patients\u2019 risk","volume":"52","author":"Koller-Smith","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.coph.2022.102242_bib58","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:06Z","timestamp":1761461826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":58,"alternative-id":["S1471489222000698"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102242","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune tolerance therapies for autoimmune diseases: Shifting the goalpost to cure","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102242"}}